Europa Biosite to Distribute Micronbrane Medical’s mNGS Technologies Across Europe
Distribution agreement introduces Micronbrane Medical’s PaRTI-Seq™ mNGS assay to European labs, enhancing infectious disease research, diagnosis and surveillance.
ZHUBEI CITY, TAIWAN, Sept 4, 2024 — Micronbrane Medical, a pioneering force in Metagenomic Next-Generation Sequencing (mNGS), today announced a distribution agreement with Europa Biosite, one of the largest distributors of life science products within Europe. The agreement enhances the capabilities of European researchers and clinical laboratories in combating infectious diseases through the adoption of Micronbrane Medical’s innovative mNGS assay.
The landscape of infectious diseases in Europe is increasingly challenging, marked by rising concerns over antimicrobial resistance (AMR) and the emergence of novel pathogens and the reemergence of communicable diseases such as tuberculosis and measles. European countries are responding by bolstering surveillance, implementing AMR stewardship programs, and adopting digital health innovations for improved disease tracking.
Additionally, climate change is expanding the range of vector-borne diseases like West Nile virus, further complicating public health efforts. The need for advanced diagnostic and surveillance methods has never been more critical.
“Our strategic emphasis is to systematically remove the barriers to ubiquitous mNGS use to improve human health,” said Dr. Mengchu Wu, CEO, co-founder, and chairwoman of Micronbrane Medical. “Our assay, Pathogen Real-Time Identification by sequencing, or PaRTI-Seq™, delivers cost-effective, comprehensive results in less than 24 hours, facilitating more comprehensive research, accurate diagnostics and tracking of all kinds of infectious diseases.”
PaRTI-Seq integrates a novel Zwitterionic host depletion filter and utilizes mNGS-grade reagents to reduce workflow contamination. It is specifically designed to accommodate low biomass samples, with a library kit capable of constructing libraries from as little as 10 picograms of DNA input. The assay also includes a specialized bioinformatic pipeline, streamlining the diagnostic process from start to finish.
“Micronbrane Medical shares our values of quality, innovation, and service,” said Martijn Blommaart, Director of Supplier Development at Europa Biosite. “We are pleased to support our customers in research and clinical laboratories in transitioning to mNGS with Micronbrane Medical’s innovative and cost-effective products.”
PaRTI-Seq™ has been validated for use with a variety of liquid biopsy samples and is already providing diagnoses as a laboratory-developed test in clinical laboratories globally. With this distribution agreement, European labs now have access to an end-to-end solution that simplifies the transition to mNGS, accelerating the adoption of precision medicine in microbiology.
About Micronbrane
At Micronbrane Medical, our mission is to develop genomic innovations that enrich our understanding of microorganisms to benefit human health and sustainability. The company’s proprietary technologies include specialized collection devices, novel host depletion, mNGS-grade reagents and consumables, advanced metagenomic sequencing assays, leading-edge automation instruments plus rapid bioinformatic analysis software. The combined Micronbrane Medical solution enables fast and accurate identification and monitoring of a broad range of microorganisms, including bacteria, fungi, viruses, and parasites. Headquartered in Taiwan, the company has partnerships and collaborations with leading academic institutions, health systems, and clinical laboratories worldwide, underscoring its commitment to transforming our relationship with microorganisms. For more information visit Micronbrane Medical.
About Europa Biosite
Europa Biosite is a European supplier of life science products and services. We are a group of six leading distribution companies: Biomol in Germany, Cambridge Bioscience in the UK and Ireland, LubioScience in Switzerland, Nordic Biosite in the Nordics and Baltics, Sanbio in Benelux and Szabo-Scandic in Austria. The group has a portfolio of over 5 million products, representation in 16 European countries and a highly skilled team of over 150 employees. For more information visit Euro Biosite.
Contacts:
Micronbrane Medical
For media and general inquiries – Kristi Ashton (kristi.ashton@micronbrane.com)
